Impactiviti Daily 082009

TODAY’S NEWS

Femara keeps breast cancer at bay better than tamoxifen – Novartis AG’s Femara prevented breast cancer from returning regardless of whether women took the drug for five years or switched to a less expensive, generic medication two years into the treatment, a study found. Initial results from the trial involving 4,922 patients found women who took Femara for five years were less likely to have the cancer return, particularly in another spot, than those who took only the generic drug tamoxifen…more

Eli Lilly stops development of bone loss drug – Eli Lilly & Co. halted development of its experimental bone drug arzoxifene, once one of its most promising new treatments, after a study found it didn’t prevent nonspinal fractures and increased blood clots and hot flashes…more

More good news for Avastin – Swiss-based Roche Holding AG said on Tuesday a study had showed its drug Avastin increased life expectancy for women with breast cancer without the disease getting worse, when used alongside common chemotherapies…more

GSK and Genmab – Arzerra results not so good – A clinical trial of Arzerra, a drug being developed by Danish biotechnology company Genmab and backed by Glaxo, had proven disappointing, Genmab management said yesterday. Among patients with non-Hodgkin’s lymphoma that were given a high dose of the drug, only 10pc saw their cancer shrink – a response rate far lower than expected…more

Eyedrops for Claritin and Zyrtec. Neither of which contain the ingredients in Claritin or Zyrtec. Hmmmm….

RECOMMENDED

Oncology training – some of my training partners specialize in training for oncology groups – product training, account management training, advanced selling skills, and much more. Contact me (stevew at impactiviti dot com, or phone at 973-947-7429) for some brainstorming and vendor recommendations to boost the performance of your oncology sales team.

PLUS

The No Drone Zone. Can you create a company of just top performers? See what Netflix has done (StickyFigure blog post).

JUST FOR FUN

I’ve got a baaaad feeling about this…

———-

Subscribe to the Impactiviti blog via e-mail

Connect with Steve Woodruff